BPC-157 ist ein synthetisches Peptid, eine im Labor hergestellte Kopie eines Fragments eines Proteins, das in der Magensaftflüssigkeit vorkommt, und wird online zum Heilen von Sehnen, Bändern und dem Darm verkauft. Fast alle Beweise für diese Anwendungen stammen aus Studien an Ratten und anderen Tieren sowie aus Zellkulturen im Labor. In diesen Modellen beschleunigt es die Heilung von durchtrennten Sehnen, Bändern und Muskeln sowie von Darmläsionen und fördert das Wachstum neuer Blutgefäße. Es gibt keine angemessene klinische Studie am Menschen, die geprüft hat, ob es bei Menschen eine dieser Wirkungen erzielt.
Es ist in keinem Land als Arzneimittel zugelassen. Es wird als Forschungschemikalie außerhalb der pharmazeutischen Kontrollen verkauft. Der Inhalt einer bestimmten Vial ist oft nicht verifiziert, und seine Langzeitsicherheit beim Menschen ist unbekannt. Es ist im Wettkampfsport verboten.
Findings & Outcomes
What It Is
BPC-157 stands for Body Protection Compound 157. It is a chain of fifteen amino acids, a pentadecapeptide, and its sequence copies part of a larger protective protein identified in human gastric juice. It is made in a laboratory, and researchers have studied this synthesized fragment since the 1990s. It resists stomach acid, which is unusual for a peptide.
It is sold online as a capsule, an oral liquid, or a powder for injection, for a long list of uses: healing tendons, ligaments, and muscle after injury, easing joint and tendon pain, healing the gut lining, and recovering faster from surgery. Almost all of the support for those uses comes from animal experiments and cell studies. It reaches buyers as a research chemical sold for laboratory use.
Anatomy
1The peptide
BPC-157 is a short synthetic peptide of fifteen amino acids. Its sequence copies a stretch of a larger protein found in human gastric juice, the fluid that protects and repairs the stomach lining. The lab-made fragment is what is studied and sold; the full natural protein it copies part of is a different molecule. Because it survives stomach acid, sellers argue it can work as a pill you swallow. That is their main case for an oral form.
2The forms sold
It is sold as oral capsules and liquids, and as a powder that buyers reconstitute and inject under the skin or near an injured tendon or joint. Most of the marketing centers on the injectable form.
What It Does
Researchers gave BPC-157 to rats and mice with surgically created injuries, by injection and in drinking water, then measured the repair. The animal doses give no guide to a human amount. In rats it speeds the healing of a surgically cut Achilles tendon and improves the recovery of movement afterward. In the same model it improves the healing of a cut knee ligament and of crushed muscle. In rat models of gut injury it heals lesions and closes fistulas, the abnormal channels that form between the bowel and nearby organs.
The animal healing signal is consistent across many studies, though it comes from a small number of laboratories, and it is the reason BPC-157 is sold. These results have not been reproduced in any human trial.
A healed wound in a rat means only that the effect may be worth testing in people; it proves nothing about people on its own.
A compound can act differently in a person than in an animal, and it can even do the opposite, or have a much larger or smaller effect.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
How it works
BPC-157 is a synthetic pentadecapeptide derived from a protein in gastric juice, stable in stomach acid
BPC-157 is a lab-made copy of a small piece of a protein found in stomach fluid. It survives stomach acid, which is unusual for a peptide. Reviews describe what it does in animals and cells; it is not the natural protein and it is not an approved medicine.
BPC-157 (Body Protection Compound 157) is a stable gastric pentadecapeptide, a synthesized partial sequence of a protein found in human gastric juice. Review articles characterize it as a cytoprotective mediator with effects on the gastrointestinal tract and vascular system observed across many preclinical experiments. These are review summaries of animal and cell work, not human outcome data.
Who this may not transfer to:This is a description of the compound and its preclinical characterization, not a measurement in people, so it conveys what BPC-157 is, not an effect size that transfers to any group.
The study · 1
Sikiric et al., Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing · Curr Pharm Des 2018;24(18):1990-2001
BPC-157 promotes new blood vessel growth through VEGFR2 in cell and animal studies
In cells grown in a dish and in animals, BPC-157 helped grow new blood vessels by switching on a receptor called VEGFR2. New blood supply is part of how any tissue repairs, which is the proposed reason it might speed healing. This is a lab observation, not a benefit shown in a person.
Hsieh and colleagues (2017) reported that the pro-angiogenic activity of BPC-157 was associated with activation and up-regulation of VEGFR2 (VEGF receptor 2) in vascular endothelial cells, with supporting effects on endothelial tube formation and vessel growth. This is a cell-level and animal mechanism study; it describes a plausible route to tissue repair but does not measure healing in humans.
Who this may not transfer to:Measured in cultured endothelial cells and animals. The angiogenic mechanism is a laboratory finding, and whether it produces any benefit in a person was not tested.
The study · 1
Hsieh et al., Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation · J Mol Med (Berl) 2017;95(3):323-333
BPC-157 sped healing of a surgically cut Achilles tendon in rats
In rats with a surgically cut Achilles tendon, BPC-157 helped the tendon heal and the animals recover movement sooner. This is an animal study; it has not been shown to heal tendons in people.
Krivic and colleagues (2008) transected the Achilles tendon-to-bone unit in rats and found that BPC-157 improved early functional recovery, in a model also used to compare it against the corticosteroid methylprednisolone. Related rat work by Chang and colleagues (2011) reported that BPC-157 promoted tendon healing with increased tendon fibroblast outgrowth, survival, and migration. These are consistent animal and cell findings; no human trial has tested tendon healing.
Who this may not transfer to:Measured in a rat tendon-transection model. The healing signal is an animal finding, and whether it occurs in a human tendon was not tested.
The study · 1
Krivic et al., Modulation of early functional recovery of Achilles tendon to bone unit after transection by BPC 157 and methylprednisolone · Inflamm Res 2008;57(5):205-210
BPC-157 improved ligament healing in rats
In rats with a cut knee ligament, BPC-157 improved healing. This is an animal study, and the same effect has not been shown in people.
Cerovecki and colleagues (2010) transected the medial collateral ligament in rats and found that BPC-157 (studied under the code PL 14736) improved ligament healing on functional, biomechanical, macroscopic, and microscopic measures. This is a controlled animal model; there is no human trial of BPC-157 for ligament injury.
Who this may not transfer to:Measured in a rat ligament-transection model. The healing effect is an animal finding, and whether it occurs in a human ligament was not tested.
The study · 1
Cerovecki et al., Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat · J Orthop Res 2010;28(9):1155-1161
BPC-157 sped recovery of crushed muscle in rats
In rats with crushed muscle, BPC-157 helped the muscle heal and regain function. This is an animal study, and it has not been shown to work the same way in people.
Novinscak and colleagues (2008) produced a crush injury of the gastrocnemius muscle complex in rats and found that BPC-157 improved healing and functional recovery. Related rat work by Staresinic and colleagues (2006) reported effective therapy of a transected quadriceps muscle. These are consistent animal findings; no human trial has tested muscle healing.
Who this may not transfer to:Measured in a rat muscle-crush model. The recovery signal is an animal finding, and whether it occurs in human muscle was not tested.
The study · 1
Novinscak et al., Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat · Surg Today 2008;38(8):716-725
BPC-157 raised growth hormone receptor expression in cultured tendon cells
In tendon cells grown in a dish, BPC-157 raised the amount of the growth hormone receptor and made the cells multiply more. This is one proposed way it might speed tendon healing. It is a cell-level lab finding, not a benefit shown in a person.
Chang and colleagues (2014) found that BPC-157 enhanced growth hormone receptor expression in cultured tendon fibroblasts and increased cell proliferation in a dose-dependent way, which the authors proposed could sensitize tendon cells to growth hormone and support tendon healing. This is an in-vitro mechanism; it does not measure tendon healing in an animal or a person.
Who this may not transfer to:Measured in cultured tendon cells. The receptor and proliferation changes are a laboratory mechanism, and whether they translate into healing in a person was not tested.
The study · 1
Chang et al., Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts · Molecules 2014;19(11):19066-19077
BPC-157 relaxed isolated human artery tissue through the nitric oxide pathway
In pieces of human artery studied in a lab dish, BPC-157 made the vessel relax through the nitric oxide pathway, the system that widens blood vessels. This is isolated-tissue evidence for how it acts on blood vessels, not a measured effect in a living person.
Yildirim and colleagues (2026) tested BPC-157 on isolated segments of human internal mammary artery and found an endothelium-dependent vasorelaxant effect mediated by nitric oxide. This adds human-tissue support for the peptide's interaction with the nitric oxide system, a pathway repeatedly implicated in its animal effects. It is an ex-vivo tissue study, not a measurement of any outcome in a living person.
Who this may not transfer to:Measured in isolated human artery tissue in the laboratory. The vasorelaxant mechanism describes how BPC-157 acts on vessels and is not an outcome measured in a living person.
The study · 1
Yildirim et al., Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery · J Clin Med 2026;15(9)
Digestion
BPC-157 healed gut lesions and closed a fistula in rats
In rats with an abnormal channel between the bowel and bladder, BPC-157 helped the channel close and the tissue heal. It has healed gut injuries in several rat models. None of this has been tested in people.
Grgic and colleagues (2016) found that BPC-157 healed colovesical fistula in rats, improving closure and tissue healing. This sits among many rat studies of BPC-157 in gastrointestinal injury and inflammatory bowel models reviewed by Sikiric and colleagues. The gut-healing evidence is consistent across animal models from a small number of laboratories; there is no adequate human trial for inflammatory bowel disease or any gastrointestinal condition.
Who this may not transfer to:Measured in a rat fistula model. The gut-healing signal is an animal finding, and whether it occurs in the human gut was not tested.
The study · 1
Grgic et al., Stable gastric pentadecapeptide BPC 157 heals rat colovesical fistula · Eur J Pharmacol 2016;780:1-7
How It Works
The mechanism described most often is angiogenesis, the growth of new blood vessels, which is part of how a tendon, ligament, or gut wall repairs. In cultured blood-vessel cells and in animals, BPC-157 promotes angiogenesis, an effect linked to activation of VEGFR2, the receptor for the main blood-vessel growth signal. That behavior appears in cultured cells; whether it heals tissue in a person is untested.
BPC-157 also interacts with the nitric oxide system, the signaling pathway that relaxes blood vessels and regulates blood flow. In human artery tissue in the lab, it made the vessel relax and widen, working through the cells that line the vessel wall. In cultured tendon cells it raised the expression of the growth hormone receptor and increased cell growth, one proposed route to faster tendon repair.
How To Think About It
How To Think About It
The healing people want from BPC-157 is best reached by the routes with human evidence behind them. The consistent tendon- and gut-healing signal in animals is a real reason the peptide is being watched. It is a legitimate target for the human trials that have not yet been run.
Tendons and muscle repair with graded loading and time. Human trials support progressive rehabilitation as the best-evidenced lever for tendon and muscle recovery.
Adequate protein supplies the building blocks for repair, and sleep is when much of that repair occurs. Both are supported by human evidence for recovery.
Go Deeper
- Peptides: the wider category BPC-157 belongs to, and how to keep the few approved peptide drugs apart from the many unregulated ones.
- TB-500: the sibling healing peptide sold the same way, with the same shape of evidence, rodent research and no completed human trial.
- Growth hormone secretagogues: the other frontier peptides sold for muscle and recovery, where the same rule about moving a marker versus changing an outcome applies.
- Resistance training: the loading that repairs and strengthens tendon and muscle, with human evidence behind it.
- Protein and muscle: what to eat to give repair its building blocks, the food-first side of recovery.
The Chinese Medicine View
No classical Chinese text describes BPC-157, a molecule synthesized in the last few decades. The tradition still offers a lens on the injury itself. Chinese medicine holds that the Spleen governs the muscles and flesh, the Liver governs the sinews, meaning the tendons and ligaments, and the Kidney governs the bones. It treats the repair of an injury as the work of Qi and Blood closing the wound. A slow-healing wound reads as a deficiency of Qi and Blood, or as stagnation blocking their flow.
The classical approach to a slow wound supports the person's own capacity to heal with herbs, food, and rest, and it does not add a single isolated agent. Here the tradition offers a caution. Building the body up helps someone who is genuinely depleted and can take in the support. Pushing a system that cannot use it only wears it down further.
Cautions
Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
The BPC-157 evidence base is preclinical, with no adequate human trial of efficacy or safety
Seiwerth and colleagues (2021) reviewed the wound-healing evidence for BPC-157 and describe a large preclinical literature in animals and cells, without an adequate human randomized trial establishing efficacy or long-term safety. The consistency of the animal signal, across many studies from a small number of laboratories, is the reason for continued interest, but the human case remains untested.Seiwerth et al., Stable Gastric Pentadecapeptide BPC 157 and Wound Healing
Sold as an unregulated research chemical
BPC-157 reaches buyers as a research chemical, with no pharmaceutical oversight, so no authority verifies its identity, dose, purity, or sterility. Testing of gray-market peptides has found wrong doses, missing active ingredient, and contamination. The injectable form adds the risk of self-injecting a nonsterile product. In the United States the FDA has flagged BPC-157 as lacking the safety data needed for pharmacy compounding.
Human safety is unknown
The safety of BPC-157 in people, including its long-term safety, has not been established. No reports of harm are not the same as proof it is safe; that only means almost no one has been studied. Anyone considering it is acting on animal data and personal reports, without the human safety record an approved medicine has.
The angiogenesis and cancer question is open
The same growth of new blood vessels that could help a wound heal is also part of how tumors grow. No long human study has looked at whether promoting angiogenesis with this peptide affects cancer risk. This concern is unconfirmed, but it is a real reason for caution in anyone with a personal or family history of cancer.
Banned in competitive sport
BPC-157 is prohibited by the World Anti-Doping Agency, which lists it among non-approved substances banned at all times. Any athlete subject to drug testing who uses it risks a sanction, and this holds whether it is taken by mouth or injected.
No data in pregnancy, breastfeeding, or children
BPC-157 has not been studied in pregnancy, breastfeeding, or children, so there is no basis for judging it safe in any of them. With no human data at all, avoiding it in these groups is the only defensible position.
A persistent injury needs a diagnosis
Persistent or severe pain, a tendon or muscle that is not recovering, or gut symptoms can signal a problem that needs a specific treatment. Self-treating with an experimental substance can delay that diagnosis. A clinician or physical therapist who can identify what is wrong is the step for a real injury.
Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.
Common Questions
Does BPC-157 actually heal tendons and injuries?
In rat studies, BPC-157 speeds tendon, ligament, and muscle repair and restores movement, and those results are consistent across many labs. In people, none of this has been shown. No trial in people has tested it for tendon, ligament, muscle, or joint injury, so the healing claims made for it online rest on animal data.
Is BPC-157 safe?
Its safety in people is unknown, because almost no one has been studied. Short-term and long-term effects in humans have not been measured. It is also sold as an unregulated research chemical, so its actual contents are often unverified. The new blood vessels it promotes raise an open question about cancer.
Is BPC-157 legal or approved?
It is not approved as a medicine in any country. It is sold as a research chemical, marketed for laboratory use, which is how it reaches buyers without going through drug approval. In the United States the FDA has said BPC-157 lacks the safety data required for pharmacy compounding. It is also banned in competitive sport by the World Anti-Doping Agency.
Is the oral or the injectable form better?
Neither has been shown to work in people, so there is no evidence-based answer. Animal studies have used both oral and injected routes. The injectable form is the one most marketed, and it adds the risks of injecting an unsterile, unverified product. Without a human trial, any choice between the two rests on animal data.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 9 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 10, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.